Skip to content
OpenCapital
Get started

C4 Therapeutics CCCC Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$6.5MMiss by $337.0KDiluted EPS-$0.37Beat by $0.01
Revenue estimate$6.8M
EPS estimate-$0.38

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$8.2M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$6.2MBeat by $1.8MQ4 2025$11.0MBeat by $5.6MQ3 2025$11.2MBeat by $6.8M
Q2 2025$6.5MMiss by $337.0K
Q1 2025$7.2MBeat by $3.7MQ4 2024$5.2MBeat by $1.8M

Diluted EPS

Q1 2026-$0.20Beat by $0.05Q4 2025-$0.18Beat by $0.13Q3 2025-$0.44Beat by $0.03
Q2 2025-$0.37Beat by $0.01
Q1 2025-$0.37Beat by $0.11Q4 2024-$0.49Miss by $0.05

Ask the moment C4 Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did C4 Therapeutics report Q2 2025 earnings?
C4 Therapeutics (CCCC) reported Q2 2025 earnings on August 7, 2025 before market open.
What were C4 Therapeutics's Q2 2025 revenue and EPS?
C4 Therapeutics reported revenue of $6.5M and diluted EPS of $-0.37 for Q2 2025.
Did C4 Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $6.8M by $337.0K. EPS beat the consensus estimate of $-0.38 by $0.01.
How did C4 Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 46.2% from $12.0M a year earlier and diluted EPS declined 42.3% from $-0.26.
Where can I find C4 Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001628280-25-038587) directly on SEC EDGAR. The filing index links above go to sec.gov.